Evidence map›Paper›PMID 24441474›Full record

ReviewNature biotechnology2014

The promise and challenge of high-throughput sequencing of the antibody repertoire.

George Georgiou, Gregory C Ippolito, John Beausang, Christian E Busse, Hedda Wardemann, Stephen R Quake

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 367 papers.

0numbers the graph read from it
0cells of the map it votes in
367citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

367 citing papers in PubMed.

  1. Trial
  2. Extending Serum IgG1 Antibody Repertoire Coverage Using DIA-PTCR.Journal of the American Society for Mass Spectrometry · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Explore antibody repertoire in the era of AI.Acta biochimica et biophysica Sinica · 2025
    Article
  14. B-EPIC: A Transformer-Based Language Model for Decoding B Cell Immunodominance Patterns.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

307 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

George Georgiou1] Department of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA. [2] Department of Biomedical Engineering, University of Texas at Austin, Austin, Texas, USA. [3] Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas, USA. [4] Institute for Cell and Molecular Biology, University of Texas at Austin, Austin, Texas, USA.
Gregory C Ippolito1] Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas, USA. [2] Institute for Cell and Molecular Biology, University of Texas at Austin, Austin, Texas, USA.
John Beausang1] Department of Bioengineering, Stanford University, Stanford, California, USA. [2] Howard Hughes Medical Institute, Stanford University, Stanford, California, USA.
Christian E BusseMax Planck Institute for Infection Biology, Berlin, Germany.
Hedda WardemannMax Planck Institute for Infection Biology, Berlin, Germany.
Stephen R Quake1] Department of Bioengineering, Stanford University, Stanford, California, USA. [2] Howard Hughes Medical Institute, Stanford University, Stanford, California, USA. [3] Biophysics Graduate Program, Stanford University, Stanford, California, USA. [4] Department of Applied Physics, Stanford University, Stanford, California, USA.

Funding

WRCE Nonhuman Primate CoreU54AI057156 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WALKER, DAVID H · 2003 to 2013
$102.6M
Howard Hughes Medical InstituteNIAID NIH HHS U54 AI057156
6 · The paper itself

Abstract

Efforts to determine the antibody repertoire encoded by B cells in the blood or lymphoid organs using high-throughput DNA sequencing technologies have been advancing at an extremely rapid pace and are transforming our understanding of humoral immune responses. Information gained from high-throughput DNA sequencing of immunoglobulin genes (Ig-seq) can be applied to detect B-cell malignancies with high sensitivity, to discover antibodies specific for antigens of interest, to guide vaccine development and to understand autoimmunity. Rapid progress in the development of experimental protocols and informatics analysis tools is helping to reduce sequencing artifacts, to achieve more precise quantification of clonal diversity and to extract the most pertinent biological information. That said, broader application of Ig-seq, especially in clinical settings, will require the development of a standardized experimental design framework that will enable the sharing and meta-analysis of sequencing data generated by different laboratories.

Indexed as

High-Throughput Nucleotide SequencingImmunoglobulinsAnimalsBiomedical ResearchHumansImmunologic TechniquesMiceModels, ImmunologicalImmunoglobulins

Identifiers

PMID24441474
PMCPMC4113560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.